Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Conditions:   Epidermolysis Bullosa;   Recessive Dystrophic Epidermolysis Bullosa Intervention:   Biological: EB-101 Sponsor:   Abeona Therapeutics, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials